Ambrx Biopharma (NYSE: AMAM)
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-10-23 | ||||||
REV |
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | ||||||
REV | 7.455M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ambrx Biopharma (NYSE: AMAM) through any online brokerage.
Other companies in Ambrx Biopharma’s space includes: Alzamend Neuro (NASDAQ:ALZN), HOOKIPA Pharma (NASDAQ:HOOK), Curis (NASDAQ:CRIS), Bolt Biotherapeutics (NASDAQ:BOLT) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Ambrx Biopharma (NYSE: AMAM) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 4.00 expecting AMAM to rise to within 12 months (a possible 77.38% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Ambrx Biopharma (NYSE: AMAM) is $2.2551 last updated Today at August 10, 2022, 6:47 PM UTC.
There are no upcoming dividends for Ambrx Biopharma.
Ambrx Biopharma’s H1 earnings are confirmed for Sunday, October 23, 2022.
There is no upcoming split for Ambrx Biopharma.
Ambrx Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.